A Dissertation for the Degree of Doctor of Philosophy

Effects of metformin on Sirt1, Nrf2 and AhR expression in cancer cells

Department of Pharmacy
Graduate School
Chungnam National University

By
Minh Truong Do

Advisor  Hye Gwang Jeong

August 2014
Effects of metformin on Sirt1, Nrf2 and AhR expression in cancer cells

Advisor  Hye Gwang Jeong

Submitted to the Graduate School
in Partial Fulfillment of the Requirements
for the Degree of
Doctor of Philosophy

April, 2014

Department of Pharmacy
Graduate School
Chungnam National University

By
Minh Truong Do
To Approve the Submitted Dissertation for the Degree of Doctor of Philosophy

By Minh Truong Do

Effects of metformin on Sirt1, Nrf2 and AhR expression in cancer cells

June, 2014

Committee Chair

Sang Kyum Kim

Committee

Bong Hee Kim

Committee

Tae Cheon Jeong

Committee

Kwang Youl Lee

Committee

Hye Gwang Jeong

Graduate School

Chungnam National University
Contents

List of Figures  vi
List of Abbreviations  x

Abstract  1

I. Introduction  6
1. Metformin and reduced risk of cancer  6
2. Role of the AhR, CYP1A1 and CYP1B1 in carcinogenesis and mechanisms of regulation of gene expression  6
3. Regulation of gene expression and role of Nrf2 and HO-1 in tumorigenesis and chemoresistance  9
4. Role of Sirt1 in tumorigenesis and chemoresistance  11

II. Materials & Methods  15
1. Materials  15
2. Cell culture and treatment  16
3. Measurement of cell viability and cytotoxicity  17
4. BrdU incorporation assay  18
III. Results  

1. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression  

1.1. Metformin inhibits CYP1A1 and CYP1B1 expression in breast cancer cells  

1.2. Down-regulation of AhR expression is required for the
suppression of CYP1A1 and CYP1B1 by metformin 33

1.3. Down-regulation of Sp1 by metformin inhibits AhR transcriptional activity in breast cancer cells 38

1.4. Inhibition of CYP1A1 and CYP1B1 expression by metformin is independent of ERα 41

1.5. Metformin suppresses endogenous AhR-ligand-induced CYP1A1 and CYP1B1 expression by reducing TDO expression in breast cancer cells 43

1.6. Metformin suppresses TDO expression by down-regulating the Sp1/glucocorticoid receptor (GR) signaling pathway 47

2. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf/ERK/Nrf2 signaling and AMPK-independent pathways 52

2.1. Metformin suppresses HO-1 expression in cancer cells 52

2.2. Metformin suppresses Nrf2 expression through a Keap1-independent mechanism in cancer cells 54

2.3. Metformin suppresses Nrf2 expression in cancer cells via Raf-ERK inactivation 58

2.4. Down-regulation of HO-1 expression by metformin is independent of AMPK 61
2.5. Reduction of HO-1 contributes to anti-proliferative effects
of metformin in cancer cells -------------------------------------------- 65

3. Metformin induces microRNA-34a to down-regulate Sirt1/Pgc-1α/Nrf2
pathway leading to increased susceptibility of cancer cells to
oxidative stress and therapeutic agents ---------------------------------- 71

3.1. Metformin suppresses Sirt1 expression in p53 wild-type
cancer cells --------------------------------------------------------------- 71

3.2. p53-dependent induction of miR-34a is required for the
reduction of Sirt1 by metformin --------------------------------------------- 73

3.3. Down-regulation of Sirt1 by metformin inhibits Nrf2 expression
and increases susceptibility of wild-type p53 cancer cells
to oxidative stress -------------------------------------------------------- 77

3.4. Metformin inhibits Nrf2 expression mediated by
suppression of Pgc-1α -------------------------------------------------------- 83

3.5. Metformin suppresses Nrf2 expression by inhibiting
PPARγ transcriptional activity and attenuating PPARγ
binding to the Nrf2 promoter -------------------------------------------------- 86

3.6. Up-regulation of DR5 expression by metformin sensitizes
wild-type p53 cancer cells to TRAIL-induced apoptosis ---------------------- 90
List of Figures

1. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression

Fig. 1. Metformin down-regulates CYP1A1 and CYP1B1 transcription in MCF-7 breast cancer cells .................................................. 31

Fig. 2. Metformin down-regulates AhR expression in MCF-7 breast cancer cells ................................................................. 35

Fig. 3. Down-regulation of AhR expression is required for the reduction of CYP1A1 and CYP1B1 by metformin in MCF-7 cells ............ 37

Fig. 4. The reduction in Sp1 protein levels mediated by metformin suppresses AhR transcriptional activity in MCF-7 breast cancer cells ........................................................................ 39

Fig. 5. Metformin down-regulates CYP1A1 and CYP1B1 expression in ERα-negative MDA-MB-231 breast cancer cells ................. 42

Fig. 6. Metformin attenuates endogenous AhR ligand-induced CYP1A1 and CYP1B1 expression by reducing tryptophan-2,3-dioxygenase expression in MCF-7 breast cancer cells ......................... 45

Fig. 7. The down-regulation of TDO expression by metformin is mediated via down-regulation of Sp1 and GR proteins ............ 49
Fig. 8. Proposed signaling pathways underlying the effects of metformin on down-regulation of CYP1A1 and CYP1B1 expression in breast cancer cells

2. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf/ERK/Nrf2 signaling and AMPK-independent pathways

Fig. 9. Metformin down-regulates HO-1 expression in various cancer cells

Fig. 10. Effects of metformin on Nrf2 and Keap1 expression in cancer cells

Fig. 11. Inactivation of Raf-ERK signaling by metformin is required for down-regulation of Nrf2 expression in cancer cells

Fig. 12. Metformin suppresses HO-1 expression in cancer cells in an AMPK-independent manner

Fig. 13. Effects of metformin on proliferation of cancer cells

Fig. 14. Role of HO-1 suppression in anti-proliferative effect of metformin in cancer cells

Fig. 15. Proposed signaling pathways underlying the effects of metformin on down-regulation of HO-1 expression in cancer cells